Navigation Links
Amicus Therapeutics to Present at the 16th Annual Future Leaders in the Biotech Industry Conference
Date:3/30/2009

CRANBURY, N.J., March 30 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company's Chief Operating Officer, Matthew R. Patterson, will be presenting at the upcoming 16th Annual Future Leaders in the Biotech Industry conference at New York City's Millennium Broadway Hotel and Conference Center. Mr. Patterson's presentation is scheduled to begin on Thursday, April 2, 2009 at 9:30 a.m. EDT.

Individuals can listen to a live webcast of the presentation by logging on to the Investors section of the Amicus Therapeutics' Web site, www.amicustherapeutics.com. Participants should allow approximately five to ten minutes prior to the presentation's start time to visit the site and download any streaming media software needed to listen to the Internet webcast. A replay of the webcast will also be available on the Company's Web site for 90 days.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs.

FOLD -G


'/>"/>
SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related biology technology :

1. Amicus Therapeutics Presents Positive Results From Phase 2 Extension Study of Amigal(TM) for Fabry Disease at ACMG 2009 Annual Meeting
2. Amicus Therapeutics to Present at the Cowen and Company 29th Annual Healthcare Conference on March 17, 2009
3. Amicus Therapeutics Announces Change to Board of Directors
4. Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results
5. Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
6. Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
7. Amicus Therapeutics to Present at Lazard Capital Markets Healthcare Conference
8. Amicus Therapeutics Announces Third Quarter 2008 Financial Results
9. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
10. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
11. Amicus Therapeutics Opens Research Facility in San Diego
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... WALTHAM, Mass., Dec. 15 Repligen Corporation ... Company has received $731,000 in research funding to ... Friedreich,s ataxia from the Muscular Dystrophy Association (MDA). ... preclinical GLP toxicology testing and GMP manufacture of ... Support from the MDA not only provides important ...
(Date:12/15/2009)... WILMINGTON, Del. and CHARLOTTESVILLE, Va., Dec. 15 ... ) and the University of Virginia (UVa) ... entered into a strategic research collaboration to ... coronary artery disease (CAD) with a secondary ... (Logo: http://www.newscom.com/cgi-bin/prnh/20091027/PH99766LOGO ) ,, The ...
(Date:12/15/2009)... The Center for Business Intelligence ... pleased to announce the full agenda for ... Reporting Congress . The forum will take ... 16-17, 2010. ,, Over 1,500 senior-level Finance, ... this premier event since its inception, and ...
(Date:12/15/2009)... launch of several innovative new programs to aid cash-strapped ... economic climate. The first is aimed at entrepreneurs ... over a period of 6, 12, 18, or 24 ... The second is aimed at more established businesses ... to 12 month period at discounted rates, and even ...
Breaking Biology Technology:Repligen Receives Second Research Grant from the Muscular Dystrophy Association to Support Friedreich's Ataxia Preclinical Development Program 2Repligen Receives Second Research Grant from the Muscular Dystrophy Association to Support Friedreich's Ataxia Preclinical Development Program 3AstraZeneca and the University of Virginia Sign Strategic Research Collaboration to Develop Novel Treatments for Cardiovascular Disease 2AstraZeneca and the University of Virginia Sign Strategic Research Collaboration to Develop Novel Treatments for Cardiovascular Disease 3CBI Announces the Agenda for Their 6th Annual Pharmaceutical/Biotech Accounting and Reporting Congress 2The Prinz Law Office Launches Innovative New Programs to Aid Cash-Strapped Entrepreneurs and Businesses 2
... Mass., Jan. 28 Joseph F. Finn, Jr.,CPA, the ... the completion the sale of the Company,s fixed assets ... 24th. In addition, due to,the high volume of requests ... of the intellectual property, the Company has,created an online ...
... Jan. 28 Carl Icahn confirmed today that,entities affiliated ... they,intend to nominate three persons at Biogen,s forthcoming 2008 ... Biogen currently,has a staggered board of twelve directors, and ... Mr. Icahn stated that "We are taking this action ...
... a Human Capillary, DUBLIN, Ireland, Jan. ... microfluidic systems in the emerging field of,nano-lifesciences, ... VenaFlux(TM),Platform. The VenaFlux(TM), the first semi-automated, high ... adhesion to,antibody-coated or endothelial- cell cultured microchannels, ...
Other Biology Technology:Icahn Confirms Intention to Nominate Three Directors at Biogen 2Icahn Confirms Intention to Nominate Three Directors at Biogen 3Cellix Ltd. Launches the First Semi-Automated, High Throughput Cell-Adhesion Assay Platform 2
(Date:12/15/2009)... This release is available in German ... laws everywhere across the globe, cultures vary as to ... example, do not use egocentric terms such as ,left, ... using allocentric notions like ,north, south, east, west, at ... of the bowl" or "There is an snake by ...
(Date:12/15/2009)... . , Leipzig: Species distribution models are of only ... This is the finding of a study of the ... analysed data on species distribution, climate, land cover and ... species. Judging by the large differences in climate niches ... fast to changing climatic conditions. This in turn makes ...
(Date:12/15/2009)... exact an enormous emotional and economic toll on society. ... rip currents each year in U.S. waters and it,s likely ... worldwide. A serious disconnect exists between rip current research ... rip tides and undertows, and more importantly, most people do ... a rip current. , The goal of the Rip Current ...
Breaking Biology News(10 mins):More than a jump to the left 2Species distribution models are of only limited value for predicting future mammal distributions 2Sagent Pharmaceuticals to Present at Piper Jaffray Health Care Conference 6454 1Neurobiological Technologies Announces Extraordinary Dividend of 240 18 per Share 6451 1Neurobiological Technologies Announces Extraordinary Dividend of 240 18 per Share 6451 2DopeStats com Provides Statistics on Oxycodone Abused in Non Medical Purposes 61912 1DopeStats com Provides Statistics on Oxycodone Abused in Non Medical Purposes 61912 2
... discovered why the aging brain produces progressively fewer ... center. The scientists said the finding, made in ... "progenitor" stem cells persist in the aging brain. ... treating various neurodegenerative disorders, including Alzheimer's disease, dementia ...
... suffer the same metabolic disorders that have led to an ... findings of research conducted at Penn State University that are ... of the Proceedings of the National Academy of Science and ... on 21 November. The discovery expands the known ...
... a finding that may provide a scientific basis for ... injury reduces the level of a protein that helps ... in turn, is thought to be an underlying reason ... have suffered a traumatic brain injury (TBI). , "A ...
Other Biology News:Stem cell activity deciphered in the aging brain 2Dragonfly's metabolic disease provides clues about human obesity 2Dragonfly's metabolic disease provides clues about human obesity 3Dragonfly's metabolic disease provides clues about human obesity 4Dragonfly's metabolic disease provides clues about human obesity 5How brain injury leads to seizures, memory problems 2
... The FRT-amp-FRT cassette is designed ... The prokaryotic promoter gb2 driving the ... modified version of the Em7 promoter. It ... used Tn5 promoter. A synthetic polyadenylation signal ...
... S-7 stirrers deliver accurate and ... fluids away from internal components. ... controls which allow users to ... tops feature a chemical resistant, ...
... loxP-cm-loxP cassette is designed ... cells. The prokaryotic promoter gb2 ... is a slightly modified version of ... transcription efficiency than the generally used ...
... This kit is designed for the fast ... vector plasmids at any position (for the ... loxP-PGK-gb2-neo-loxP cassette is designed to allow neomycin ... cells. It combines a prokaryotic promoter (gb2) ...
Biology Products: